Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial.
(2025) Clinical infectious diseases — Vol. 80, n° 2, p. 367-370 (2025)
Files
2024_Lamberink_Clin_Infect_Dis.pdf
Open Access - Adobe PDF
- 269.06 KB
Details
- Authors
Lamberink, Hanne 
Huygens, Sammy Aerts, Robina Lagrou, Katrien Rijnders, Bart
- Abstract
- The IA-DUET study aimed to compare azole-echinocandin combination with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
- Affiliations
Citations
Lamberink, H., Huygens, S., Aerts, R., Lagrou, K., van Leeuwen-Segarceanu, E., Lodewyck, T., Nieuwenhuizen, L., Corsten, M. F., Moors, I., Servais, S., De Greef, J., Hites, M., Demandt, A., Schauwvlieghe, A., Maertens, J., & Rijnders, B. (2025). Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial. Clinical infectious diseases, 80(2), 367-370. https://doi.org/10.1093/cid/ciae501 (Original work published 2025)